Slide 1: H1 2026
H1 2026 Lars Bering, CEO Allan Jeppesen, CFO 20 August 2026 SP Group
Slide 2: SP Group Executive Board
SP Group Executive Board Lars Bering Søren Ulstrup Allan Malmos Jeppesen CEO Executive Vice President CFO SP Group H1 2026 – 20 August 2026 2
Slide 3: At a glance
At a glance Global manufacturer of plastics solutions SP Group’s sales in H1 2026 broken down by product group: Foodtech 76% 24% customer-specific subsupplier projects own products Healthcare 14% Global 35 35% Other footprint factories 22% 3,039 employees 18% recycled plastics Cleantech SP Group H1
Slide 4: SP Group – Advanced plastics solutions
SP Group – Advanced plastics solutions Ergomat SP Medical TPI-Polytechniek MedicoPack Ergonomic solutions for Guide wires for Components for Packaging for industrial work environments pharmaceutical use livestock housing ventilation the pharmaceutical industry Nycopac SP Tinby SP Moulding SP Meditec
Slide 5: Global focus
Global focus Geographic location of SP Group’s companies and breakdown of global sales in 2025 Sales and production 27% • Denmark (15) • Poland (6) • China (2) Denmark • USA (3) • Latvia (1) • Slovakia (2) • Sweden (1) • Finland (2) 0 47% • India (1) • United Kingdom (2) 16% Europe (excluding 10% No
Slide 6: Highlights (1/2)
Highlights (1/2) Record Q2 2026 • Revenue growth of 44.6% - of which 29.4% organic growth • EBITDA margin of 20.3% • EBT margin of 12.4% Record H1 2026 • Revenue growth of 32.9% - of which 19.7% organic growth • EBITDA margin of 20.3% • EBT margin of 12.7% • Growth in own products and subsupplier pr
Slide 7: Highlights 2/2
Highlights 2/2 • Expansion of medical device production in Poland • Integration of Idé-Pro is in progress • Acquisition of OGM Moulding Ltd. Outlook upgraded at 19 August 2026: • Revenue growth of 24–30% • EBITDA margin of 19–21% • EBT margin of 11–13% SPUnited OGM, Gibo, Denmark Kingdom SP Group H1
Slide 8: Growth in sales of own products
Growth in sales of own products Revenue, own products Own products include pharmaceutical packaging, guide DKKm wires, livestock housing ventilation systems, maritime +21.6% products, ergonomic solutions, etc. 472 391 388 317 226 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 SP Group H1 2026 – 20 August 2
Slide 9: Growth in subsupplier tasks
Growth in subsupplier tasks Revenue, subsupplier projects DKKm +37.0% 1.478 1.259 1.053 1.079 1.010 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 SP Moulding Stoholm, Denmark SP Group H1 2026 – 20 August 2026 9
Slide 10: Product groups, H1 2026
Product groups, H1 2026 Healthcare 35% Cleantech 29% Foodtech 14% Other 22% • Medical devices • Renewable energy • Food industry • Automotive • Pharmaceutical packaging • Energy reduction • Livestock housing ventilation • Maritime products • Ergonomics and safety • Insulation products • Measuring eq
Slide 11: Acquisition of OGM 1/3
Acquisition of OGM 1/3 S T R E N GT H S : • Modern production facilities and a well-established platform in the United Kingdom • Customers within medtech, safety equipment and transport • Leading UK subsupplier of injection-moulded precision components • Long-standing customer relationships • Certif
Slide 12: Acquisition of OGM 2/3
Acquisition of OGM 2/3 S T R AT E G I C R AT I O N A L E : Medtech as a strategic growth area Box-Build – new capabilities Strengthens our position in one of the Group’s most important Sourcing, testing and assembly of electronic and plastic growth areas and supports the One-Stop Shop strategy. comp
Slide 13: Acquisition of OGM 3/3
Acquisition of OGM 3/3 T H E T R A N S ACT I O N Purchase price: GBP 18.0m Fixed purchase price (approx. DKK 158m) Earn-out: Up to GBP 6.0m Earn-out (approx. DKK 53m) conditional on earnings in 2027 and 2028 EV/EBITDA approx. 4.8 Assuming full realisation of the earn-out OGM, United Kingdom SP Group
Slide 14: Investment in Healthcare in Poland
Investment in Healthcare in Poland Expansion of production in Poland: • Focus on capacity, efficiency and space utilisation • Conversion of 7,000 m2 building for medical device production • New 1,700 m2 cleanroom facilities ready for production Inauguration of SP Meditec’s new cleanroom facilities i
Slide 15: Financial highlights, Q2 2026 1/3
Financial highlights, Q2 2026 1/3 Revenue EBITDA DKKm DKKm +44.6% 984 +59.9% 200 762 154 680 663 681 120 125 103 Q2 2022 Q2 2023 Q2 2024 Q2 2025 Q2 2026 Q2 2022 Q2 2023 Q2 2024 Q2 2025 Q2 2026 EBIT EBT DKKm DKKm 140 +86.4% +91.9% 122 104 92 75 75 71 64 51 40 Q2 2022 Q2 2023 Q2 2024 Q2 2025 Q2 2026 Q
Slide 16: Financial highlights, H1 2026 2/3
Financial highlights, H1 2026 2/3 Revenue EBITDA DKKm DKKm +32.9% +36.2% 1.950 397 1.401 1.370 1.485 1.467 302 291 250 230 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 EBIT EBT DKKm DKKm 280 +45.4% +50.3% 248 203 192 162 176 165 153 130 108 H1 2022 H1 2023 H1 2024
Slide 17: Financial highlights, H1 2026 3/3
Financial highlights, H1 2026 3/3 Cash flows from operating activities increased by DKK 62 Earnings per share, diluted, increased by 55.1% million DKK DKKm 16,49 291 257 229 11,34 187 9,92 10,63 137 6,92 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 H1 2022 H1 2023 H1 2024 H1 2025 H1 2026 Net interest-bea
Slide 18: Revenue performance
Revenue performance DKKm 3.432 2.922 2.948 2.656 2.606 2.481 2.178 2.013 1.884 1.965 1.519 1.320 1.109 1.102 1.165 977 852 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 LTM Revenue for 2026 is stated on a rolling 12-month basis SP Group H1 2026 – 20 August 2026 18
Slide 19: EBITDA and EBITDA margin performance
EBITDA and EBITDA margin performance DKKm % 800 EBITDA growth of 36.2% in H1 2026 700 20.4% EBITDA-margin in % • Margin improvement of 6.4 701 600 EBITDA percentage points since 2016 500 • Margin improvement driven by: 400 – Increased share of own products – Increased share of value chain 300 14.0%
Slide 20: EBT and EBT margin performance
EBT and EBT margin performance DKKm EBT growth of 50.3% in H1 2026 % 500 • Margin improvement of 4.5 EBT-margin in % percentage points since 2016 12.5% 400 EBT • Margin improvement driven by: 428 – Increased share of own products 300 – Increased share of value chain – Production expansion in Eastern
Slide 21: Key figures and financial ratios
Key figures and financial ratios DKKm Q2 2026 Q2 2025 H1 2026 H1 2025 2025 Revenue 984 681 1,950 1,467 2,948 EBITDA 200 125 397 291 595 EBIT 140 75 280 192 398 EBT 122 64 248 165 345 EPS, diluted (DKK) 16.49 10.63 22.1 Equity 1,900 1,701 1,809 Cash flows from: - operating activities 132 98 291 229 3
Slide 22: Outlook for 2026
Outlook for 2026 The revenue guidance for 2026 is upgraded, while the guidance for earnings margins is maintained Original guidance Updated guidance Updated guidance at 25 March 2026 at 10 July 2026 at 19 August 2026 Revenue growth 15–23% 22–28% 24–30% EBITDA margin 19–21% unchanged unchanged EBT ma
Slide 23: Summary
Summary 1. Strong organic growth in H1 2026 2. Growth in sales of own products and subsupplier projects 3. OGM Moulding Ltd. 4. Access to a new market and new customers in the United Kingdom 5. Full-year 2026 guidance upgraded MedicoPack, Denmark SP Group H1 2026 – 20 August 2026 23
Slide 24: Q&A session
Q&A session SP Group 24
Slide 25: Further information: Lars Bering CEO
Further information: Lars Bering CEO SP Group A/S Snavevej 6-10 5471 Søndersø Denmark Tel.: +45 7023 2379 / +45 4033 8850 E-mail: lb@sp-group.dk SP Group